Develops immunotherapies for cancer and autoimmune diseases.
Jun 2025Revenue A$10.3M/yrExpenses A$71.8M/yr
No trend
Figures by year
When will IMMUTEP be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2025, revenue was A$10.3M and expenses A$71.8M.
| Fiscal year to | Revenue | Expenses | Pre-tax profit |
|---|---|---|---|
| Jun 2025 | A$10.3M | A$71.8M | −A$61.4M |
| Jun 2024 | A$7.84M | A$50.6M | −A$42.7M |
| Jun 2023 | A$5.20M | A$45.1M | −A$39.9M |
| Jun 2022 | A$6.76M | A$39.0M | −A$32.2M |
| Jun 2021 | A$3.97M | A$33.9M | −A$29.9M |
| Jun 2020 | A$16.5M | A$30.0M | −A$13.5M |
| Jun 2019 | A$7.49M | A$25.8M | −A$18.3M |
| Jun 2018 | A$7.35M | A$20.1M | −A$12.7M |
| Jun 2017 | A$4.22M | A$14.3M | −A$10.1M |
| Jun 2016 | A$2.03M | A$65.2M | −A$63.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.